Actavis to reintroduce FeverAll
MORRISTOWN, N.J. Actavis on Tuesday announced the reintroduction of its FeverAll acetaminophen suppositories to retail following the completion of updates to the company’s manufacturing facility.
The brand will be marketed in publications read by new parents and healthcare professionals, the company stated.
FDA issues warning about MMS use
ROCKVILLE, Md. The Food and Drug Administration on Friday issued a warning to consumers not to take Miracle Mineral Solution, an oral liquid also known as “Miracle Mineral Supplement” or “MMS.”
The product, when used as directed, produces an industrial bleach that can cause serious harm to health.
The FDA has received several reports of health injuries from consumers using this product, including severe nausea, vomiting, and life-threatening low blood pressure from dehydration.
Consumers who have MMS should stop immediately using it and throw it away.
MMS is distributed on Internet sites and online auctions by multiple independent distributors. Although the products share the MMS name, the look of the labeling may vary.
The product instructs consumers to mix the 28% sodium chlorite solution with an acid such as citrus juice. This mixture produces chlorine dioxide, a potent bleach used for stripping textiles and industrial water treatment. High oral doses of this bleach, such as those recommended in the labeling, can cause nausea, vomiting, diarrhea and symptoms of severe dehydration.
MMS claims to treat multiple unrelated diseases, including HIV, hepatitis, the H1N1 flu virus, common colds, acne, cancer and other conditions. The FDA is not aware of any research that MMS is effective in treating any of these conditions. MMS also poses a significant health risk to consumers who may choose to use this product for self-treatment instead of seeking FDA-approved treatments for these conditions.
The FDA continues to investigate and may pursue civil or criminal enforcement actions as appropriate to protect the public from this potentially dangerous product.
The FDA advises consumers who have experienced any negative side effects from MMS to consult a healthcare professional as soon as possible and to discard the product.
Study: Vitamin D deficiency may lead to arterial stiffness in black teens
CHEVY CHASE, Md. Vitamin D deficiency is associated with arterial stiffness, a risk factor for heart disease and stroke in African-American teens, according to a new study accepted for publication on The Endocrine Society’s website, Endo-society.org.
“While we think of the sun as providing humans with most of our body’s requirement of vitamin D, 95% of the 44 black teenagers living in sunny Georgia who took part in this study were classified as vitamin D deficient,” stated Yanbin Dong, lead author of the study. “Our study shows that vitamin D supplementation may improve cardiovascular health in black teens who don’t get enough vitamin D from their diet and sun exposure.”
In this study, 44 black teenagers (male and female) were randomly assigned to receive either 400 IU of vitamin D per day as recommended by the American Academy of Pediatrics or 2,000 IU of vitamin D per day. Study subjects taking 400 IU of vitamin D per day did not achieve vitamin D sufficiency, while their peers who took 2,000 IU of vitamin D per day on average became vitamin D sufficient.
Black teens taking vitamin D supplementation of 2,000 international units (IU) per day had a decrease in central arterial stiffness.
“Our study is the first clinical trial of vitamin D intervention to use 2,000 IU in black subjects and to include cardiovascular risk factors as outcomes in youth,” Dong said. “Our study indicates that the current recommendations for vitamin D intake in black teenagers may need to be revised upward.”